Biogen vs Neurocrine Biosciences: revenue, profit, margins and growth compared
Biogen brought in $9.9B of revenue in fiscal 2025, Neurocrine Biosciences $2.9B in fiscal 2025. Revenue changed by +2.2% at Biogen and +21.4% at Neurocrine Biosciences on the year before, so Neurocrine Biosciences grew faster. Biogen kept 13.1% of its revenue as net profit, Neurocrine Biosciences 16.7%. Free cash flow was $2.1B at Biogen and $748.7M at Neurocrine Biosciences.
Fiscal years as each company reports them; the two may end in different months.
Questions about Biogen and Neurocrine Biosciences
Which is bigger by revenue, Biogen or Neurocrine Biosciences?
Biogen is bigger by revenue: $9.9B in fiscal 2025, against $2.9B for Neurocrine Biosciences in fiscal 2025.
Which keeps more of its revenue as profit, Biogen or Neurocrine Biosciences?
Biogen had a net margin of 13.1% in fiscal 2025; Neurocrine Biosciences had 16.7% in fiscal 2025.
Which grew revenue faster, Biogen or Neurocrine Biosciences?
In their latest fiscal years revenue changed by +2.2% at Biogen and +21.4% at Neurocrine Biosciences.
Where do these numbers come from?
From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.